Although the social media platform has cleaned up its content, this investigation shows clinicians still need to be aware of where their patients are getting information.
COBRA investigators will evaluate circulating tumor DNA (ctDNA) as a biomarker for adjuvant chemotherapy benefit in 1408 patients with resected, stable stage IIA colon cancer.
Combination tivozanib and durvalumab was found to be well-tolerated in patients with advanced, treatment-naïve hepatocellular carcinoma (HCC).
LEAP-005 investigators tested the safety and efficacy of combination lenvatinib and pembrolizumab in 32 patients with previously treated advanced non–microsatellite instability-high (MSI-H)/mismatch repair proficient (pMMR) colorectal cancer (CRC).
Investigators reviewed data from 202,237 patients from the Surveillance, Epidemiology, and End Results (SEER) registry who had been diagnosed CRC with 2010 and 2015.
Investigators developed a clinical score to address how to categorize patients with well-differentiated neuroendocrine tumors (NETs) who are being considered for peptide receptor radionuclide therapy (PRRT) and how to sequence therapy.
Post-hoc analysis sought to determine whether a causal relationship exists between treatment with osimertinib and development of cardiac failure.
Mistrust and concerns about masculinity are important factors that influence Black men’s experience during prostate cancer management.
Adult-onset cancer survivors have greater risk for subsequent primary cancer; majority of these incidences are cancers associated with obesity or smoking
A survey of patients with cancer treated in radiation clinics of a major New York metropolitan cancer center reported satisfaction with telemedicine care, compared with in-person visits.
Please login or register first to view this content.
